Furthermore, in the MRL-lpr mouse model of arthritis, treatment with an MCP-1 antagonist, MCP-1 (9–76), prior to disease onset greatly reduced OA progression whereas native MCP-1 enhanced the onset and aggravated joint inflammation [46]. Here, CCL2 is linked to arthritic joint disease.